Jones, CM, Brunelli, A, Callister, ME et al. (1 more author) (2018) Multimodality Treatment of Advanced Non-small Cell Lung Cancer: Where are we with the Evidence? Current Surgery Reports, 6 (2). 5. ISSN 2167-4817
Abstract
Purpose of review The majority of patients with non-small cell lung cancer (NSCLC) present with advanced disease and overall survival rates are poor. This article outlines the current and outstanding evidence for the use of multimodality treatment in this group of patients, including in combination with an increasing number of treatment options, such as immunotherapy and genotype-targeted small molecule inhibitors. Recent findings Optimal therapy for surgically resectable stage III disease remains debatable and currently the choice of treatment reflects each individual patient’s disease characteristics and the expertise and opinion of the thoracic multi-disciplinary team. Evidence for a distinct oligometastatic state in which improved outcomes can be achieved remains minimal and there is as yet no consensus definition for oligometastatic lung cancer. Whilst there is supporting evidence for the aggressive management of isolated metastases, the use of consolidative therapy for multiple metastases remains unproven. Summary Evolution of new RT technologies, improved surgical technique and a plethora of interventional-radiology-guided ablative therapies are widening the choice of available treatment modalities to patients with NSCLC. In the setting of resectable locally advanced disease and the oligometastatic state, there is a growing need for randomised comparison of the available treatment modalities to guide both treatment and patient selection.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
Keywords: | Lung cancer; Treatment; Radiotherapy; Stereotactic ablative radiotherapy; Chemotherapy; Surgery; Locally advanced; Oligometastatic |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Biological Sciences (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 13 Mar 2018 11:03 |
Last Modified: | 13 Apr 2018 13:27 |
Status: | Published |
Publisher: | Springer Verlag |
Identification Number: | 10.1007/s40137-018-0202-0 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:128115 |